Clinical Study Evaluating the Outcomes of a New Knee System with a Physiological Rollback Mechanism

NCT ID: NCT02118272

Last Updated: 2025-03-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 156 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-31
• Study Completion Date: 2021-11-30

Brief Summary

The aim of this study is to assess the clinical, radiographic and patient-reported outcome measures (PROMs) after total knee replacement with Physica KR, define the survivorship of the implants and identify possible risk factors that may lead to failure.

Conditions

Primary Total Knee Replacement

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Physica KR

Group Type: OTHER

Physica KR

Intervention Type: DEVICE

Interventions

Physica KR

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Male and females

2. Age 22-80 years

3. Any race

4. Ambulatory patients

5. Patients who have a medical condition with over 5 years of life expectancy

6. Patients requiring knee prosthesis, suitable for the use of Physica KR

7. Patients with painful primary knee osteoarthritis

8. Patients with painful secondary knee osteoarthritis

9. Patients who are suffering from inflammatory arthritis (e.g. rheumatoid arthritis)

10. Patients who have undamaged and functional collateral and posterior cruciate ligaments

11. Patients with a flexion greater than or equal to 90° on the affected side

12. Patients with a fixed flexion contracture less than 10°

13. Patients who understand the conditions of the study and are willing and able to comply with the prescribed rehabilitation and to perform all scheduled follow-up visits

14. Patients who have signed the Ethics Committee approved study-specific Informed Consent Form prior to the surgery

Exclusion Criteria

1. Obese patients with BMI above 35 kg/m2 (severe obesity)

2. Previous partial knee replacement (unilateral, bicompartimental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or femoral osteotomy in the affected knee

3. Primary Total Knee Replacement (TKR) in the affected knee

4. Varus or Valgus deformity greater than 20°

5. Patients with a fixed flexion contracture greater than 10°

6. Previous knee replacement on the contralateral side within the last year and whose outcome is achieving an KSS< 70 points

7. Patients with symptomatic OA of the hips, spine, ankles, if it can interfere with the evaluation of the target knee

8. Patients with active or any suspected infection (on the affected knee or systemic)

9. Muscular insufficiency or absence of muscoligamentous supporting structures required for adequate soft tissue balance

10. Patients with known or suspicious metal hypersensitivity

11. Recurrent medical history of severe allergic or immune-mediated reactions

12. Vascular insufficiency of lower limbs severe enough to interfere with the study evaluation

13. Current treatment or treatment within the previous 2 years before the screening visit for malignant and life-threatening non-malignant disorders

14. Any clinically significant pathology based on clinical history that the Investigator feels may affect the study evaluation

15. Any intercurrent chronic disease or condition that may interfere with the completion of the 5-year follow-up, such as liver disease, severe coronary disease, alcohol or drug abuse, disordered mental state, or other clinically significant condition

16. Patients who have significant neurological or musculoskeletal disorders or disease that may adversely affect gait and compromise functional recovery and evaluation

17. Patients who have neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device

18. Patients with systemic or metabolic disorders leading to progressive bone deterioration

19. Patients who have a medical condition with less 5 years of life expectancy

20. Previous organ transplant surgery

21. Any psychiatric illness that would prevent comprehension of the details and nature of the study

22. Participation in any experimental drug/device study within the 6 months prior to the screening visit

23. Female patients who are pregnant, nursing, or planning a pregnancy

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Limacorporate S.p.a

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Azienda Ospedaliero-universitaria Careggi

Florence, Florence, Italy

The Royal Bournemouth Hospital, NHS Foundation Trust

Bournemouth, Dorset, United Kingdom

Dorset County Hospital NHS Foundation Trust

Dorchester, Dorset, United Kingdom

Countries

Italy; United Kingdom

Other Identifiers

K-06 Physica KR

Identifier Type: -

Identifier Source: org_study_id